Article thumbnail
Location of Repository

The effect of iron depletion on chronic hepatitis C virus infection

By Massimo Franchini, Giovanni Targher, Franco Capra, Martina Montagnana and Giuseppe Lippi

Abstract

Increasing evidence exists that iron overload, a common finding in chronic hepatitis C virus (HCV) infection, plays an important role in the pathophysiology of this disease. The mechanisms by which iron excess induces liver damage along with the benefit of iron depletion via phlebotomy on biochemical and histological outcomes in patients with chronic HCV infection have been discussed in this review. Finally, we focus on the effect of iron reduction on the rate of response to interferon antiviral therapy

Topics: Review Article
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2716881
Provided by: PubMed Central

Suggested articles

Citations

  1. (1998). A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C.
  2. (1999). A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon.
  3. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan.
  4. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C. Hepatogastroenterology 2005;52:563–566.
  5. (2000). Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol
  6. (2000). C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis. Arch Pathol Lab Med
  7. (2001). Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis
  8. (2004). Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int
  9. (2008). Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gatroenterol 2005;40:901–906. Hepatol Int
  10. (1995). Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy.
  11. (2007). Effect of iron depletion on serum markers of fibrogenesis, oxidative stress, serum liver enzymes in chronic hepatitis C: results of a pilot study. Liver Int
  12. Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study.
  13. HALT-C Trial Group. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440–1451.
  14. Hemochromatosis gene modifies course of hepatitis C viral infection.
  15. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis.
  16. Hemochromatosis, transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.
  17. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitisC.
  18. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995;108:1104–1109.
  19. (2008). Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin
  20. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.
  21. hepatic stellate cells and fibrosis in chronic hepatitis C.
  22. (1998). Hepaticironoverloadinpatientswithchronicviralhepatitis:roleof HFE gene mutations. Hepatology
  23. Hepatitis C virus infection.
  24. (2005). Hepatotoxicity of iron overload: mechanisms of iron induced hepatic fibrogenesis. Semin Liver Dis
  25. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695–1699.
  26. (2000). Heterozygosity for the hemochromatosis gene in liver diseases— prevalence and effects on liver histology. Liver
  27. (2003). HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis. Rev Esp Enferm Dig
  28. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.
  29. (1994). Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron.
  30. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course.
  31. (1997). Iron and chronic viral hepatitis. Hepatology
  32. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis
  33. (2002). Iron as a cofactor in chronic hepatitis C infection. Liver
  34. Iron as a comorbid factor in chronic viral hepatitis.
  35. Iron depletion and response to interferon in chronic hepatitis C. Hepato-gastroenterology 2003;50:1467–1471.
  36. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to Interferon therapy.
  37. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations.
  38. (2000). Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver
  39. (2002). Iron in hepatitis C: villain or innocent bystander? Semin Gastroenterol Dis
  40. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study.
  41. (2000). Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology
  42. (2000). Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology
  43. Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C.
  44. iron status, and disease severity: relationship with HFE mutations.
  45. (1996). Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver
  46. Long-term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C.
  47. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C.
  48. (1992). Measurements of iron status in patients with chronic hepatitis.
  49. Molecular mechanism of iron metabolism and overload in chronic hepatitis
  50. Normalization of elevated hepatic 8-hydroxy2’-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet.
  51. (2008). Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci
  52. (2002). Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver
  53. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis.
  54. (1996). Retreatment of hepatitis C interferon nonresponders with larger doses of interferon with and without phlebotomy. Hepato-gastroenterology
  55. (1995). Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C.
  56. (2002). Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology
  57. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C.
  58. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127–134.
  59. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248–252.
  60. (1997). Therapy of hepatitis C: other options. Hepatology
  61. (1997). Tsai NCS,ZuckermanE,Han SH,GoadK,Redeker AG,FongTL. Effect of iron depletion on long-term response to interferon-alpha inpatientswithchronichepatitisCwhopreviouslydidnotrespond to interferon therapy.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.